Different metrics should be used in different settings to measure ARV program success

Noting the recent publication in Science of two studies showing "the profound impact of antiretroviral-therapy coverage at a population level" -- how wider coverage can increase life expectancy and reduce the risk of HIV infection -- Grace John-Stewart, a professor at the University of Washington School of Medicine, writes in a Nature opinion piece, "These data ... should persuade policymakers to sustain or increase investment in this form of therapy." She continues, "It is clear from the two studies that for regions of high HIV prevalence, including South Africa, greater investment in antiretroviral therapy is essential. To attain one of the goals of the Joint United Nations Program on HIV/AIDS (UNAIDS) -- 15 million individuals on antiretroviral therapy by 2015 -- continued support from [the Global AIDS Program] and PEPFAR will be necessary."

"At a national or global policy level, antiretroviral therapy has been the subject of scrutiny in many ways," such as "for its dual treatment and prevention benefits" or "for the potential strain the therapy places on health systems," but "[a]ntiretroviral-therapy programs have led to broad improvements in health systems, innovations in clinical education and overhauls of laboratory and clinical infrastructure -- much more than the global community initially envisioned," John-Stewart writes. "Financial investments were linked to measurable and diverse beneficial outcomes," she notes. She concludes, "For the future, it remains important to wrestle with what outcomes are most relevant to health-resource investment decisions," saying "other metrics, including comparisons with other health investments and impact on morbidity, quality of life or productivity, may be more useful in lower-prevalence settings" (3/27).

Print This ArticlePrint Entire Report

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel antiviral protein SAMD9L blocks HIV-1 and other lentiviruses